Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database

Objective Amifampridine is the first drug approved specifically for Lambert-Eaton myasthenic syndrome (LEMS), but its safety profile is still not fully understood. This study aimed to systematically detect and characterize post-marketing adverse event signals of amifampridine using the FDA Adverse Event Reporting System (FAERS). Methods Case reports from FAERS between Q1 2004 and Q2 2026 were analyzed. Disproportionality analysis was performed using four algorithms: the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-gamma Poisson shrinker (MGPS); only events meeting all four criteria were retained as signals. Time-to-onset (TTO) was analyzed with a Weibull distribution, and sex stratified analyses were conducted. Results A total of 2,893 reports involved amifampridine as the primary suspect drug. Most reports came from the United States (98.1%) and were submitted by consumers (82.0%). Signals were concentrated in the nervous and gastrointestinal systems, consistent with known cholinergic toxicity, including oral and pharyngeal paraesthesia, hypoaesthesia, and abdominal discomfort. Notably, a cluster of bladder-related events including hypertonic bladder, bladder pain, bladder spasm, and incontinence was identified that is not listed in the prescribing information. Median TTO was 658 days, and the Weibull shape parameter (β = 0.889, 95% CI 0.840–0.937) indicated an early-failure pattern. Sex-stratified analysis showed distinct reporting patterns between males and females. Conclusion Most identified signals were consistent with the established cholinergic toxicity of amifampridine. Previously unreported adverse event signals, such as bladder-related events, were also identified. These findings indicate that long-term monitoring of adverse events associated with amifampridine is necessary to improve patient safety.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.2013910
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database

Chuang Yang, Chen Wang
4 links
Frontiers in Pharmacology
Pharmacovigilance and Adverse Drug Reactions
article

Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database

Chuang Yang, Chen Wang
article en

Abstract

Objective Amifampridine is the first drug approved specifically for Lambert-Eaton myasthenic syndrome (LEMS), but its safety profile is still not fully understood. This study aimed to systematically detect and characterize post-marketing adverse event signals of amifampridine using the FDA Adverse Event Reporting System (FAERS). Methods Case reports from FAERS between Q1 2004 and Q2 2026 were analyzed. Disproportionality analysis was performed using four algorithms: the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-gamma Poisson shrinker (MGPS); only events meeting all four criteria were retained as signals. Time-to-onset (TTO) was analyzed with a Weibull distribution, and sex stratified analyses were conducted. Results A total of 2,893 reports involved amifampridine as the primary suspect drug. Most reports came from the United States (98.1%) and were submitted by consumers (82.0%). Signals were concentrated in the nervous and gastrointestinal systems, consistent with known cholinergic toxicity, including oral and pharyngeal paraesthesia, hypoaesthesia, and abdominal discomfort. Notably, a cluster of bladder-related events including hypertonic bladder, bladder pain, bladder spasm, and incontinence was identified that is not listed in the prescribing information. Median TTO was 658 days, and the Weibull shape parameter (β = 0.889, 95% CI 0.840–0.937) indicated an early-failure pattern. Sex-stratified analysis showed distinct reporting patterns between males and females. Conclusion Most identified signals were consistent with the established cholinergic toxicity of amifampridine. Previously unreported adverse event signals, such as bladder-related events, were also identified. These findings indicate that long-term monitoring of adverse events associated with amifampridine is necessary to improve patient safety.

Frontiers in PharmacologyVol. 17
The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Children's Hospital of Chongqing Medical University (CN), Chongqing Medical and Pharmaceutical College (CN), Chongqing Medical University (CN)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon